ARWR - Amgen Compelling On New Data And Biosimilar Approval June, 14 2022 03:57 AM Arrowhead Pharmaceuticals Inc. Amgen’s Lumakras revenue is ramping rapidly. Amgen Phase 2 topline olpasiran data was positive. Amgen rheumatoid arthritis biosimilar received FDA approval. For further details see: Amgen Compelling On New Data And Biosimilar Approval